A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.
Standard
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. / Fehm, Tanja; Braun, Stephan; Müller, Volkmar; Janni, Wolfgang; Gebauer, Gerhard; Marth, Christian; Schindlbeck, Christian; Wallwiener, Diethelm; Borgen, Elin; Naume, Bjorn; Pantel, Klaus; Solomayer, Erich.
in: CANCER-AM CANCER SOC, Jahrgang 107, Nr. 5, 5, 2006, S. 885-892.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.
AU - Fehm, Tanja
AU - Braun, Stephan
AU - Müller, Volkmar
AU - Janni, Wolfgang
AU - Gebauer, Gerhard
AU - Marth, Christian
AU - Schindlbeck, Christian
AU - Wallwiener, Diethelm
AU - Borgen, Elin
AU - Naume, Bjorn
AU - Pantel, Klaus
AU - Solomayer, Erich
PY - 2006
Y1 - 2006
N2 - Numerous single-institutional studies and a large pooled analysis have demonstrated that the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) from patients with primary, nonmetastatic breast cancer (Stages I-III) is associated with impaired prognosis. To date, sampling of BM and assessment of DTCs is not considered a routine procedure in the clinical management of breast cancer patients; however, emerging data suggest a future role for risk stratification and monitoring of therapeutic efficacy. Because these clinical options need to be evaluated in trials to verify the principle of this concept in the clinical setting, agreement on the standardized detection of DTCs is necessary. Consequently, the German, Austrian, and Swiss Societies for Senology recently formed a panel 1) to review and discuss the existing methodologies, 2) to find a consensus for a standardized detection of DTCs, and 3) to explore the options for its clinical implementation.
AB - Numerous single-institutional studies and a large pooled analysis have demonstrated that the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) from patients with primary, nonmetastatic breast cancer (Stages I-III) is associated with impaired prognosis. To date, sampling of BM and assessment of DTCs is not considered a routine procedure in the clinical management of breast cancer patients; however, emerging data suggest a future role for risk stratification and monitoring of therapeutic efficacy. Because these clinical options need to be evaluated in trials to verify the principle of this concept in the clinical setting, agreement on the standardized detection of DTCs is necessary. Consequently, the German, Austrian, and Swiss Societies for Senology recently formed a panel 1) to review and discuss the existing methodologies, 2) to find a consensus for a standardized detection of DTCs, and 3) to explore the options for its clinical implementation.
M3 - SCORING: Zeitschriftenaufsatz
VL - 107
SP - 885
EP - 892
JO - CANCER-AM CANCER SOC
JF - CANCER-AM CANCER SOC
SN - 0008-543X
IS - 5
M1 - 5
ER -
